An important milestone for people living with fibrodysplasia ossificans progressiva (FOP). The @FDA has approved an oral ALK2 inhibitor developed by Incyte and licensed to @mirumpharma for worldwide development and commercialization. Learn more in the press release. bit.ly/4rxVfza

Here’s a look at where data from the Incyte portfolio will be throughout this year’s #EADVCongress. We look forward to connecting with the dermatology community and advancing important scientific conversations. bit.ly/4iJuS73

Join us at the upcoming European Academy of Dermatology and Venereology (EADV) Congress where we will share our latest scientific advancements in inflammation and autoimmunity. Learn more about our data. #EADVCongress bit.ly/4dtDsDk

We're attending the @nbd_foundation's 78th Annual Bleeding Disorders Conference (BDC) in Orlando, August 13–15. Our team is excited to listen to, learn from and connect with the bleeding disorders community. #BDC2026

Patients guide our work in dermatology. Hervé Lamarque, Division Vice President, Head of Business Unit Inflammation & Autoimmunity (IAI) International, shares how Incyte’s commitment to the global dermatology community helps shape our research and innovation. bit.ly/44VPJvQ

Atopic dermatitis (AD) is a chronic inflammatory skin disease that can affect daily life. Learn more about AD and our commitment to patients. bit.ly/44VPJvQ

Incyte announces @EU_Commission approval of our topical JAK treatment for adults with moderate atopic dermatitis. Read to learn more. bit.ly/4ftTxul

Read our press release to learn more about Incyte’s Q2 financial results and business updates. bit.ly/4hkgZLZ

We’ll be presenting data from our Oncology pipeline at the @myESMO 2026 Congress in Madrid. Highlights include updates from our KRAS G12D inhibitor in pancreatic cancer and our TGFβR2×PD-1 bispecific antibody in colorectal cancer. Join us at #ESMO26 to explore the data and what’s next across our oncology portfolio. bit.ly/4w8ni9E

We’re focused on building a portfolio of scientifically differentiated compounds designed to make a meaningful impact for patients. Learn more about von Willebrand disease (VWD), the most common inherited bleeding disorder, and the data presented at this year’s #ISTH2026 Congress. bit.ly/4vuZnQU

Data from our Phase 1/2 multidose study in von Willebrand disease (VWD) was presented at the @isth Congress. Learn more about the data. #ISTH2026 bit.ly/4ydqJ0h

For the first time since acquiring VGA039 (latarcibart), we’re sharing data at the @isth Congress. We look forward to connecting with researchers, clinicians and partners from around the world as we seek to advance care for patients.

Approximately 135,000 people in the U.S. are living with von Willebrand disease (VWD). Learn more about this condition and our commitment to advancing therapies for diseases with significant unmet need. bit.ly/4fj3bzE

Today, we completed our acquisition of Vega Therapeutics, expanding our hematology portfolio into bleeding disorders by adding a differentiated late-stage program for von Willebrand disease (VWD). Read our press release to learn more. bit.ly/4vPMzph

#News: The #CHMP of the @EMA_News has issued a positive opinion for our treatment for moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. Learn more: bit.ly/3SMIHqa

#News: Japan’s Ministry of Health, Labour and Welfare (MHLW) approved our treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Learn more. bit.ly/4fQDdnZ

Pablo Cagnoni reflects on the importance of the new data we shared for our mutCALR-targeted monoclonal antibody in patients with myeloproliferative neoplasms (MPNs) at the @EHA_Hematology Congress. #EHA2026 bit.ly/4awns1W

We shared new positive data for our mutCALR-targeted monoclonal antibody in patients with myelofibrosis (MF) and essential thrombocythemia (ET) at the @EHA_Hematology Congress. Learn more about these data. #EHA2026 bit.ly/4oqcgcQ

We are proud to share Phase 3 data at the @EHA_Hematology Congress, underscoring our commitment to advancing care for patients with diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 bit.ly/4gouMjM

Today, the prestigious Plenary Abstracts Session at the @EHA_Hematology Congress highlighted data from the Phase 3 frontMIND trial for patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL). Learn more. #EHA2026 bit.ly/4v45iwN